Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 12, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences to Effect a Reverse Stock Split
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
- Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to…
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study DURHAM, N.C. --(BUSINESS WIRE)--Dec. 13, 2023-- Precision…
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
- Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity - mitoARCUS efficiently shifted…
Precision BioSciences to Present at Hep-DART 2023
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
- PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA - Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at…
Precision BioSciences to Present at Upcoming Sidoti Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Company to Host Webcast and Conference Call on Monday, November 13, 2023 at 4:30 PM ET DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene…
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 - Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline - Expanded…